AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- A participant in the CHM CORE-NK Phase 1b trial with advanced Acute Myelogenous Leukemia (AML) has achieved a complete response.
- The trial combines NK cells with Vactosertib to treat advanced colorectal and blood cancers.
- A patient from the previous Phase 1a trial also achieved a complete response, which has been sustained for 48 months.
- The trial is led by Dr. Eva Selfridge at UH Seidman Cancer Center in Ohio and aims to enrol 12 patients.
Chimeric Therapeutics Limited (ASX:CHM) has provided a promising update on its ongoing CHM CORE-NK phase 1b clinical trial, which assesses the combination of NK cells with Vactosertib in patients diagnosed with advanced colorectal and blood cancers. The company reported that one participant with advanced Acute Myelogenous Leukemia (AML) has achieved a complete response in the trial. This patient is the first and only one treated in the blood cancer arm of the trial.
As part of the trial, this patient will remain in the study and will be monitored for up to 15 years, in accordance with FDA requirements for cell therapy trials.
This significant development builds on results from the Phase 1a trial, in which a different patient also achieved a complete response that has now been sustained for 48 months.
About the CHM CORE-NK + Vactosertib Phase 1b clinical trial
The Phase 1b trial builds on the clinical outcomes observed in the preliminary CHM CORE-NK Phase 1a trial by combining NK cells with Vactosertib. Vactosertib is an oral TGF-β receptor inhibitor that aims to disrupt the inhibitory TGF-β signaling pathway.
Notably, this is the first trial ever to evaluate the combination of Vactosertib and NK cells in participants with blood and advanced colorectal cancers. The trial, which is being conducted at UH Seidman Cancer Center in Ohio under the leadership of Dr. Eva Selfridge, targets the treatment of 12 patients, with three patients currently enrolled.
CHM CORE-NK is manufactured at a cost to CHM, but the trial itself is being conducted without financial support from the company.
About CHM CORE-NK
Data source: Company update
CHM shares traded at AU$0.014 apiece on 30 September 2024.
